Evicenter
Vyndamax (tafamidis) in Transthyretin amyloid cardiomyopathy
Manufacturer
Pfizer Inc
Questions
71
Last updated

All questions

Clinical trials: Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy

10 questions · 4 sources

Clinical trials

What trial supported Vyndamax approval (ATTR-ACT)?

Who was eligible for ATTR-ACT, the trial behind Vyndamax approval?

Study results

Vyndamax ATTR-ACT trial: did Vyndaqel reduce death and cardiovascular hospitalizations?

Note: Table 2 columns are pooled VYNDAQEL (N=264) and placebo (N=177), in that order. ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Vyndamax ATTR-ACT trial: how much did Vyndaqel lower the risk of death?

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Vyndamax ATTR-ACT trial: did Vyndaqel reduce cardiovascular hospitalizations vs placebo?

Note: Table 3 columns are pooled VYNDAQEL (N=264) and placebo (N=177), in that order. The patient-years figure is from the efficacy page of the Vyndamax HCP site, which cites Maurer and Mann, JACC Basic Transl Sci 2018. ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Vyndamax ATTR-ACT trial: did Vyndaqel slow decline in walking distance and KCCQ score?

Note: Table 4 values follow the header order: baseline mean (SD) for pooled VYNDAQEL and placebo, change from baseline to Month 30 as LS mean (SE) for pooled VYNDAQEL and placebo, and the treatment difference from placebo as LS mean (95% CI). ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Vyndamax ATTR-ACT trial: did NT-proBNP and troponin favor Vyndaqel over placebo?

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Vyndamax ATTR-ACT trial: did Vyndaqel 20 mg and 80 mg give similar results?

Subgroup results

Vyndamax ATTR-ACT trial: were Vyndaqel results consistent across subgroups?

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

Long-term results

Vyndaqel and Vyndamax: what was 5-year survival in the ATTR-ACT extension?

Note: The extension compared continuous tafamidis (VYNDAQEL 80 mg, then VYNDAMAX) with patients who received placebo in ATTR-ACT and then tafamidis. The additional data page of the Vyndamax HCP site cites Elliott et al., Circ Heart Fail 2022.